Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Life Science Investor Conference, Økonomisk Ugebrev, Copenhagen (October 2024)
20 slides from Cantargia Ab's conference presentation, Oct 30, 2024
Slide 1: Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases
Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases Corporate Presentation October 2024 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Cantargia – Investment highlights
Cantargia – Investment highlights NOVEL IL1RAP ANTIBODIES, POTENTIAL TO TREAT CANCER & INFLAMMATORY DISEASE • IL1RAP elevated in most solid and liquid tumors • IL1RAP signaling drives several autoimmune and inflammatory diseases NADUNOLIMAB: CLEAR ACTIVITY SIGNALS IN CANCER THERAPY WITH UPCOMING CAT
Slide 4: Current pipeline
Current pipeline Asset Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 PDAC**, Nadunolimab TNBC*, NSCLC** Hidradenitis Suppurativa CAN10 Systemic Sclerosis New opportunities within CANxx IL1RAP platform PDAC – pancreatic cancer; TNBC – triple-negative breast cancer; NSCLC – non-small cell l
Slide 5: CAN10 – Opportunity in autoimmune/inflammatory disease
CAN10 – OPPORTUNITY IN AUTOIMMUNE/INFLAMMATORY DISEASE
Slide 6: CAN10 developed to block IL-1 family with precision
CAN10 developed to block IL-1 family with precision • CAN10 prevents signaling from IL1/, IL-33 and IL36// • CAN10 binds IL1RAP with pM affinity and prevents IL1RAP interaction with the IL-1, IL-33 and IL-36 receptors • CAN10 has shown robust efficacy in preclinical models of several diseases •
Slide 7: CAN10 first-in-human study - SAD part
CAN10 first-in-human study - SAD part Design Results • Blinded, placebo-controlled study • No safety signals • Nine dose groups from 1 to 400 mg CAN10 incl. 2 patients on • Receptor occupancy documented (at Cmax) placebo in each group • Potent PD effects on IL-1 & IL-36 at Cmax and day 8 IL-36 stimu
Slide 8: CAN10 First-in-Human study - MAD part
CAN10 First-in-Human study - MAD part Psoriasis 6 Design Total score (0-8) Vehicle 4 • SC administration in subjects with mild to moderate plaque psoriasis (MAD) Ctrl Anti-IL-1β Anti-IL-1β • Two dose levels 2 Ctrl mCAN10 mCAN10 Dexamethasone • Six treated with CAN10, two with placebo, in each group
Slide 9: Overview of Hidradenitis Suppurativa (HS)
Overview of Hidradenitis Suppurativa (HS) HS – a severe chronic inflammatory skin disease • HS is a diverse disease with several inflammatory components involved in the pathology • Estimated HS prevalence of 0.7-1.2% Inadequate current treatments • Antibiotics • Steroids • Anti-TNFα (Humira), anti-I
Slide 10: CAN10 for treatment of Hidradenitis Suppurativa (HS)
CAN10 for treatment of Hidradenitis Suppurativa (HS) IL-36R-blockade (spesolimab) elicited positive results on overall disease severity1 • Efficacy shown in Phase 2 randomized controlled study (NCT04762277) by changes in iHS4, HASI-R, and HiSCR50, with a particular effect on draining tunnels (dTs) •
Slide 11: Systemic sclerosis – mCAN10 inhibits bleomycin-induced skin fibrosis
Systemic sclerosis – mCAN10 inhibits bleomycin-induced skin fibrosis Bleomycin (BLM) model mCAN10 10 mg/kg twice W BLM 2.5 mg/kg (daily s.c.) Nintedanib 50 mg/kg QD C57BL/6 Established fibrosis Termination n=10 per group Week 3 Week 6 No BLM (6 wks) Baseline BLM (3 wks) Dermal thickness Myofibroblas
Slide 12: Nadunolimab (CAN04) overview
NADUNOLIMAB (CAN04) OVERVIEW
Slide 13: IL1RAP overexpressed in most solid tumors
IL1RAP overexpressed in most solid tumors IL1RAP EXPRESSION IN SOLID TUMOR TYPES SEVERAL TUMOR-PROMOTING CELLS EXPRESSING IL1RAP IN THE TUMOR MICROENVIRONMENT 100% IL1RAP-expressing tumors 75% 50% 25% 0% C ic as t al r ea l C er CL at e ct iL ve g SC d N S r e B r r e ha N lad nc lo op H B Pa Co Es
Slide 14: Pancreatic Cancer – Positive data in 1st line patients
Pancreatic Cancer – Positive data in 1st line patients OS and iPFS for mITT patients Best responses according to iRECIST 50% Best change in tumor size 0% -50% -100% iCPD iUPD iSD iPR Nadunolimab combination with Gem/Abraxane in 1st line PDAC (n=73): → 33% response rate with long OS and iPFS → Additi
Slide 15: Pancreatic cancer – Efficacy (1st line with gem/abraxane)
Pancreatic cancer – Efficacy (1st line with gem/abraxane) OS by IL1RAP subgroup IL1RAP High IL1RAP Low 50% Best change in tumor size iCPD 0% iUPD iSD iPR -50% -100% → IL1RAP linked to specific KRAS mutations and worse prognosis → Significantly prolonged OS in ILRAP High vs IL1RAP Low patients (14.2
Slide 16: Nadunolimab and alleviation of neuropathy
Nadunolimab and alleviation of neuropathy CORRELATION BETWEEN NADUNOLIMAB DOSE LEVEL AND DECREASE IN NEUROPATHY SIMILAR POSITIVE EFFECTS IN COMBINATION WITH OXALIPLATIN 16
Slide 17: NSCLC – Strongest effects in patients no longer responding to PD1-inhibitors
NSCLC – Strongest effects in patients no longer responding to PD1-inhibitors SUBGROUP ANALYSIS FROM 40 PATIENTS SHOW VERY STRONG DATA IN 2ND LINE NON-SQ NSCLC, A GROUP WITH HIGH MEDICAL NEED
Slide 18: Milestones & Investment Highlights
MILESTONES & INVESTMENT HIGHLIGHTS
Slide 19: Upcoming milestones
Upcoming milestones Nadunolimab Additional PDAC TNBC AML/MDS CAN10 milestones • Phase 2b trial in 150- • Randomized Phase 2 • Start phase 1/2 Q4 • Phase 1 final data H1 • New preclinical and 200 patients top-line data in H1 2024 (DOD sponsored 2025 translational results 2025 with MDA*) • Start phase
Slide 20: Cantargia – Investment highlights
Cantargia – Investment highlights NOVEL IL1RAP ANTIBODIES, POTENTIAL TO TREAT CANCER & INFLAMMATORY DISEASE • IL1RAP elevated in most solid and liquid tumors • IL1RAP signaling drives several autoimmune and inflammatory diseases NADUNOLIMAB: CLEAR ACTIVITY SIGNALS IN CANCER THERAPY WITH UPCOMING CAT
Cantargia — Life Science Investor Conference, Økonomisk Ugebrev, Copenhagen (October 2024) on 6ix